CN1126546C - 使用胞磷胆碱减少梗塞面积 - Google Patents
使用胞磷胆碱减少梗塞面积 Download PDFInfo
- Publication number
- CN1126546C CN1126546C CN96193176A CN96193176A CN1126546C CN 1126546 C CN1126546 C CN 1126546C CN 96193176 A CN96193176 A CN 96193176A CN 96193176 A CN96193176 A CN 96193176A CN 1126546 C CN1126546 C CN 1126546C
- Authority
- CN
- China
- Prior art keywords
- citicoline
- purposes
- pharmaceutical salts
- ischemia
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (35)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39926295A | 1995-03-06 | 1995-03-06 | |
US08/399,262 | 1995-03-06 | ||
US08/603,102 | 1996-02-20 | ||
US08/603,102 US5872108A (en) | 1995-03-06 | 1996-02-20 | Reduction of infarct volume using citicoline |
US08/609,448 US5827832A (en) | 1995-03-06 | 1996-03-01 | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
US08/609,448 | 1996-03-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021458014A Division CN1488353A (zh) | 1995-03-06 | 1996-03-06 | 用于治疗发生缺血患者的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1181015A CN1181015A (zh) | 1998-05-06 |
CN1126546C true CN1126546C (zh) | 2003-11-05 |
Family
ID=27410335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96193176A Expired - Lifetime CN1126546C (zh) | 1995-03-06 | 1996-03-06 | 使用胞磷胆碱减少梗塞面积 |
CNA021458014A Pending CN1488353A (zh) | 1995-03-06 | 1996-03-06 | 用于治疗发生缺血患者的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021458014A Pending CN1488353A (zh) | 1995-03-06 | 1996-03-06 | 用于治疗发生缺血患者的组合物 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0813416B1 (zh) |
JP (1) | JPH11511732A (zh) |
CN (2) | CN1126546C (zh) |
AT (1) | ATE296103T1 (zh) |
AU (1) | AU5304796A (zh) |
BR (1) | BR9607206A (zh) |
CA (1) | CA2213000A1 (zh) |
DE (1) | DE69634773T2 (zh) |
ES (1) | ES2244968T3 (zh) |
MX (1) | MX9706808A (zh) |
NO (1) | NO313538B1 (zh) |
PL (1) | PL185124B1 (zh) |
PT (1) | PT813416E (zh) |
WO (1) | WO1996027380A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
CA2316989A1 (en) * | 1997-12-24 | 1999-07-08 | Interneuron Pharmaceuticals, Inc. | Hyperhydrated citicoline, process and use |
US6225444B1 (en) | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
ES2169986B1 (es) * | 2000-03-14 | 2003-06-16 | Ferrer Int | Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral. |
ATE345799T1 (de) | 2001-10-15 | 2006-12-15 | Janssen Pharmaceutica Nv | Substituierte 4-phenyl-4-(1h-imidazol-2-yl)- piperidinderivate zur verringerung von ischämischer schädigung |
ES2345802B1 (es) * | 2009-03-30 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus. |
ES2743767T3 (es) | 2012-05-31 | 2020-02-20 | Univ Kinki | Agente para prevenir y/o tratar dolor neuropático periférico causado por un fármaco anticancerígeno |
JP6166786B2 (ja) * | 2012-10-30 | 2017-07-19 | 協和発酵バイオ株式会社 | 脳機能低下の予防または改善剤 |
CN105769882B (zh) * | 2016-03-14 | 2019-02-22 | 北京赛德维康医药研究院 | 一种抑制血栓形成的药物组合物及其用途 |
AU2017413260B2 (en) | 2017-05-09 | 2023-07-06 | Fundacio De Recerca Clínic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer | Composition comprising uric acid for the treatment of brain stroke patients treated with mechanical thrombectomy |
US11497795B2 (en) | 2018-09-28 | 2022-11-15 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
IT1207106B (it) * | 1980-04-18 | 1989-05-17 | Made Italiana Srl Ora Searle I | Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale |
-
1996
- 1996-03-06 CN CN96193176A patent/CN1126546C/zh not_active Expired - Lifetime
- 1996-03-06 WO PCT/US1996/003159 patent/WO1996027380A1/en active IP Right Grant
- 1996-03-06 EP EP96909616A patent/EP0813416B1/en not_active Expired - Lifetime
- 1996-03-06 CA CA002213000A patent/CA2213000A1/en not_active Abandoned
- 1996-03-06 CN CNA021458014A patent/CN1488353A/zh active Pending
- 1996-03-06 JP JP8527057A patent/JPH11511732A/ja active Pending
- 1996-03-06 AT AT96909616T patent/ATE296103T1/de not_active IP Right Cessation
- 1996-03-06 DE DE69634773T patent/DE69634773T2/de not_active Expired - Lifetime
- 1996-03-06 PL PL96322061A patent/PL185124B1/pl unknown
- 1996-03-06 ES ES96909616T patent/ES2244968T3/es not_active Expired - Lifetime
- 1996-03-06 PT PT96909616T patent/PT813416E/pt unknown
- 1996-03-06 BR BR9607206A patent/BR9607206A/pt not_active Application Discontinuation
- 1996-03-06 AU AU53047/96A patent/AU5304796A/en not_active Abandoned
-
1997
- 1997-09-04 NO NO19974076A patent/NO313538B1/no not_active IP Right Cessation
- 1997-09-05 MX MX9706808A patent/MX9706808A/es unknown
Non-Patent Citations (2)
Title |
---|
《山东医药》31(8) 1991-08-31 张桂森等抗栓酶-3胞二磷胆碱治疗脑血栓形成33例疗效观察 * |
《新药与临床》2(1) 1983-01-31 尹宗信等胞二磷胆碱治疗脑损害16例的临床观察 * |
Also Published As
Publication number | Publication date |
---|---|
PL322061A1 (en) | 1998-01-05 |
ES2244968T3 (es) | 2005-12-16 |
CN1181015A (zh) | 1998-05-06 |
AU5304796A (en) | 1996-09-23 |
JPH11511732A (ja) | 1999-10-12 |
NO974076L (no) | 1997-10-28 |
PT813416E (pt) | 2005-10-31 |
CN1488353A (zh) | 2004-04-14 |
NO313538B1 (no) | 2002-10-21 |
EP0813416A1 (en) | 1997-12-29 |
NO974076D0 (no) | 1997-09-04 |
DE69634773D1 (de) | 2005-06-30 |
DE69634773T2 (de) | 2006-05-04 |
BR9607206A (pt) | 1997-11-11 |
EP0813416B1 (en) | 2005-05-25 |
MX9706808A (es) | 1998-08-30 |
PL185124B1 (pl) | 2003-02-28 |
WO1996027380A1 (en) | 1996-09-12 |
ATE296103T1 (de) | 2005-06-15 |
EP0813416A4 (en) | 2000-11-15 |
CA2213000A1 (en) | 1996-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1126546C (zh) | 使用胞磷胆碱减少梗塞面积 | |
Hensley et al. | American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants | |
CN100427081C (zh) | 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物 | |
CN101563079B (zh) | 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途 | |
KR19980702724A (ko) | 시티콜린을 이용한 경색크기의 감소 방법 | |
US5827832A (en) | Method of protecting brain tissue from cerebral infarction subsequent to ischemia | |
CN113398144B (zh) | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 | |
CN110167595A (zh) | 非酒精性脂肪性肝病的预防及治疗药 | |
DE69727240T2 (de) | Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV | |
Jäger et al. | Health and ergogenic potential of oral adenosine-5′-triphosphate (ATP) supplementation | |
Ranjan et al. | Advances in therapies to treat neonatal hypoxic-ischemic encephalopathy | |
ES2925775T3 (es) | Esteres de ácido azelaico en el tratamiento de la resistencia a la insulina | |
CN108904516A (zh) | 肌苷在防治抑郁症中的应用 | |
AU2002300446B2 (en) | Reduction of infarct volume using citicoline | |
AU2005201251A1 (en) | Reduction of infarct volume using citicoline | |
NZ337305A (en) | Use of citicoline to reduce the extent of infarction subsequent to a ischemic event | |
JP2006342184A (ja) | シチコリンを用いる梗塞容積の低減 | |
Lasser et al. | The influence of aureomycin on human coagulability | |
Carter et al. | Thermal injury and gastrointestinal function II. Evidence for the production of hepatic dysfunction in the rat following acute burn injury | |
RU2448706C2 (ru) | Инъекционная форма фармацевтической композиции (варианты) для профилактики и лечения заболеваний нервной системы и способ ее изготовления | |
CN104586835B (zh) | 穿心莲内酯的医药用途 | |
Bannock | Cellfood DNA/RNA is being replace with Methusalife DNA/RNA, developed by Dr. Todd Ovokaitys. | |
Kobets et al. | Drug prescription to patients with depression: results of frequency analysis | |
JP2023519536A (ja) | 神経学的疾患及び状態の予防及び治療のためのn-アセチルシステインとニコチンアミドリボシドとを含む組成物及び方法 | |
Pliner et al. | Cytotoxic Agents and Immune |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: FERRER INTERNAC S. A. Free format text: FORMER OWNER: YINGDEWUSI PHARMACEUTICAL CO., LTD. Effective date: 20101112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: YINGDEWUSI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: INTERNEURON PHARMACEUTIC CO. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: MASSACHUSETTS, USA TO: BARCELONA, SPAIN |
|
CP01 | Change in the name or title of a patent holder |
Address after: Massachusetts USA Patentee after: Germany Wusi Pharmaceutical Co.,Ltd. Address before: Massachusetts USA Patentee before: INTERNEURON PHARMACEUTICALS, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101112 Address after: Barcelona Patentee after: FERRER INTERNACIONAL, S.A. Address before: Massachusetts USA Patentee before: Germany Wusi Pharmaceutical Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20031105 |
|
EXPY | Termination of patent right or utility model |